History
Corporate Milestone
2016
Feb
JW Therapeutics founded in Shanghai
Jul
GMP cell therapy manufacturing infrastructure first put into use
2017
Jul
Introduced world-class CAR-T technology platform and completed technology development
2018
May
Completed series A financing totaling over USD100 million
Sep
JW Therapeutics (Suzhou) Co., Ltd. founded
Nov
Started world-leading commercial scale cell therapy manufacturing project
Dec
JW Therapeutics R&D center opened
2019
Feb
Recognized as a “Foreign-invested R&D center” by Shanghai Municipal People’s Government
Oct
Outstanding Enterprise in the Growth Group of the China Innovation and Entrepreneurship Competition of the Ministry of Science and Technology
Dec
Completed cell therapy commercial- scale manufacturing infrastructure in Suzhou
Dec
GMP quality management lab put into use
2020
Jan
Zhangjiang Science City Outstanding Enterprise Innovation and Development Award
May
Completed USD100 million series B financing
Jun
Acquired Syracuse Biopharma
Jun
Suzhou site obtained drug manufacturing license
Nov
Listed on the main board of the Hong Kong Exchanges and Clearing Limited, stock code 2126.HK
2021
Sep
Became the market authorization holder (MAH) for cell therapy product, and entered commercial stage
2022
Feb
Shanghai CAR-T Cell Immunotherapy Technology Innovation Center
Dec
High-tech enterprises
2023
Mar
Specialized, Refined, Distinctive and Innovative SMEs in Shanghai
Dec
Pudong New Area Research and Development Institutions
2024
Jul
JW Therapeutics Appoints Min Liu as Chief Executive Officer
Dec
“CNR” Corporate Social Responsibility ESG Era Pioneer Award
2025
Mar
JW Therapeutics Appoints Min Liu as Chairman of the Board
Product Milestone
2017
Dec
Relma-cel* was infused for treatment in the first patient
2018
Jun
Relma-cel obtained first approval for clinical trial of CAR-T product targeting CD19 under IND pathway in China
2019
Apr
Successfully introduced BCMA-targeted cell therapy drug candidate (codename: JWCAR129)
Jun
Relma-cel was included in the National Significant New Drug Development Program
Dec
Relma-cel was included in the National Significant New Drug Development Program
2020
Jun
Successfully submitted relma-cel’s NDA for its first indication LBCL
Sep
Relma-cel was granted priority review for its new drug application, and Breakthrough Therapy Designation
2021
Sep
Relma-cel was approved and launched in China
Sep
Received the IND approval for clinical trial of JWCAR129
2022
Mar
Received the IND clearance for clinical trial of Carteyva® on 2L LBCL
Apr
Received the IND clearance for clinical trial of Carteyva® on pALL
Apr
CARTEYVA® has been granted Breakthrough Therapy Designation in China for the indication of mantle cell lymphoma (MCL)
Jun
Initiated the clinical study in solid tumors, and infused the first HCC patient for treatment
Sep
Relma-cel was approved for FL indication in China
2023
Jan
Carteyva® was included in the“Shanghai Recommended Catalogue of Innovative Products”
Apr
The clinical trial application for the indication of CARTEYVA® 2L LBCL (adult relapsed or refractory large B-cell lymphoma after first-line treatment failure and unsuitable for high-dose chemotherapy and autologous stem cell transplantation) has been approved.
Apr
The clinical trial application for CARTEYVA® in systemic lupus erythematosus (SLE) has been approved
May
Carteyva® was included in the“Shanghai Biopharmaceutical Product Catalogue of ‘New and Excellent Drug and Equipment’”
Jun
Carteyva® was included in the“Shanghai Pudong New Area Recommended Catalogue of Innovative Drug and Equipment”
2024
Mar
Carteyva® received Shanghai High-tech Achievements Transformation Certification
Jul
Carteyva® was included in the“Suzhou Famous and Innovative Products in Biopharmaceutical and Health Industry”
Aug
CARTEYVA® has been approved in China for the indication of mantle cell lymphoma (MCL)
2025
Jan
The indication of CARTEYVA® 2L LBCL (relapsed or refractory large B-cell lymphoma in adults who are not suitable for high-dose chemotherapy and autologous stem cell transplantation after first-line treatment failure) has been granted Breakthrough Therapy Designation in China
* Relmacabtagene autoleucel injection (relma-cel): JW Therapeutics’ lead product with trade name Carteyva®, and codename JWCAR029